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Abstract: Many plant-derived, dietary polyphenols have been studied for their 
chemopreventive and chemotherapeutic properties against human cancers, including green 
tea polyphenols, genistein (found in soy), apigenin (celery, parsley), luteolin (broccoli), 
quercetin (onions), kaempferol (broccoli, grapefruits), curcumin (turmeric), etc. The more 
we understand their involved molecular mechanisms and cellular targets, the better we 
could utilize these “natural gifts” for the prevention and treatment of human cancer. 
Furthermore, better understanding of their structure-activity relationships will guide 
synthesis of analog compounds with improved bio-availability, stability, potency and 
specificity. This review focuses on green tea polyphenols and seeks to summarize several 
reported biological effects of tea polyphenols in human cancer systems, highlight the 
molecular targets and pathways identified, and discuss the role of tea polyphenols in the 
prevention and treatment of human cancer. The review also briefly describes several other 
dietary polyphenols and their biological effects on cancer prevention and chemotherapy. 
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1. Introduction 
It is estimated by the American Cancer Society that in 2007, there will have been more than 12.3 
million new cancer cases and 7.6 million deaths from cancers worldwide [1]. How to decrease cancer 
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incidence and mortality has been a major challenge in this endeavor. The growing amount of evidence 
from studies in epidemiology, cell cultures and animal tumor models demonstrates that a large number 
of natural compounds from the diet could lower cancer risk and some of them could sensitize tumor 
cells in anti-cancer therapies [2-5]. For cancer prevention and chemotherapy, plant-derived natural 
compounds are an invaluable treasure and worthy to be further explored. In this review we summarize 
the effects of some well studied natural compounds, with green tea polyphenols as a focus, against 
cancers and their potential molecular targets. 
2. Natural Compounds and Their Molecular Targets for Cancer Prevention and Treatment 
2.1. Tea Polyphenols 
The history of tea began in ancient China over 5,000 years ago. Tea, of all varieties, is the most 
widely consumed beverage in the world today, and is consumed by 1/3 of the world’s population. 
Green tea, black tea, and oolong tea are all derived from the Camellia sinensis plant. Of all the teas 
consumed in the
 world, green tea is well studied for their health benefits [6]. It is generally agreed that 
the cancer chemopreventive
  effects of green tea are mediated by its abundant polyphenol, 
epigallocatechin gallate [(-)-EGCG]. 
2.1.1. (-)-EGCG Inhibit Proteasome Activity in Tumor Cells 
It has been suggested that proteasome activity is essential for tumor cell proliferation and drug 
resistance development. Therefore, the proteasome-mediated degradation pathway has been considered 
an important target for cancer prevention and therapy. The proteasome inhibitor Bortezomib (Velcade, 
PS-341) has been used in clinical trials and its antitumor activity has been reported in a variety of 
tumor models [7-9]. The ubiquitin/proteasome system controls the turn-over of critical regulatory 
proteins involved in several cellular processes such as cell cycle and apoptosis [10, 11]. Under normal 
conditions, the lysosomal pathway degrades extracellular proteins imported into the cell by 
endocytosis or pinocytosis, whereas the proteasome controls degradation of intracellular proteins [10, 
12]. The eukaryotic proteasome contains at least three known catalytic activities: chymotrypsin-like, 
trypsin-like, and caspase-like or peptidyl-glutamyl peptide-hydrolyzing (PGPH)-like activities [13]. 
Our laboratory and others, have reported that inhibition of the proteasome chymotrypsin-like activity 
is associated with induction of apoptosis in tumor cells [14, 15]. We reported that (-)-EGCG potently 
and specifically inhibited the chymotrypsin-like
 activity of the proteasome in vitro (IC50 = 86-194 nM) 
and in vivo (1-10 µM) at the concentrations found in the serum of green
 tea drinkers and induced tumor 
cell growth arrest in G1 phase of the cell cycle [16]. We also reported for the first time, that an ester 
bond within (-)-EGCG played a critical role in its inhibitory activity of the proteasome [16]. We found 
that synthetic (-)-EGCG amides and (-)-EGCG analogs, with modifications in the A-ring, C-ring or 
ester bond, inhibited the chymotrypsin-like activity of purified 20S proteasome with altered potencies, 
induced growth arrest in the G1 phase of the cell cycle in leukemia Jurkat T cells, and suppressed 
colony formation of human prostate cancer LNCaP cells. However, these EGCG analogs caused little 
or no proteasome inhibition in normal or non-transformed cells [17]. Int. J. Mol. Sci. 2008, 9 
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(-)-EGCG remains the most potent polyphenol in green tea, but one of the limitations of (-)-EGCG 
is its instability in neutral or alkaline conditions (i.e. physiologic pH). In an effort to discover more 
stable polyphenol proteasome inhibitors, we synthesized several (-)-EGCG analogs with -OH groups 
eliminated from the B- and/or D-rings. In addition, we also synthesized their putative prodrugs with -
OH groups protected by acetate that can be removed by cellular cytosolic esterases. We first examined 
the structure-activity relationship of these unprotected and protected compounds with respect to their 
proteasome inhibitory potentials. We found that decreasing -OH groups from either the B- or D-ring 
leads to diminish proteasome-inhibitory activity in vitro. However, in cultured tumor cells, the 
protected analogs were able to inhibit the proteasomal chymotrypsin-like activity by as much as 97% 
[18]. Furthermore, we found that the protected analogs exhibited greater potency compared to (-)-
EGCG regarding inhibited proliferation and transforming activity and induction of apoptosis in human 
leukemic, prostate, breast, and simian virus 40-transformed cells [19, 20]. The protected analogs were 
non-toxic to human normal and non-transformed cells [19, 20]. 
2.1.2. (-)-EGCG Protects DNA from Methylation 
In the process of carcinogenesis, a carcinogen may cause changes in gene functions and/or in gene 
constructions. Epigenetic silencing by hypermethylation of tumor suppressor or DNA repair-related 
genes occurs more frequently during the early stages of the neoplastic process and may result in 
carcinogenesis in cells [21]. 
It has been reported that silencing of the O
6-methylguanine-DNA methyltransferase gene (MGMT) 
results in cells with the ability to acquire a specific type of genetic mutation in p53, and subsequently, 
an inability to repair DNA guanosine adducts [22]. 
Fang  et al. [23] reported that (-)-EGCG could inhibit the activity of DNA methyltransferase 
(DNMT), resulting in CpG demethylation and reactivation of methylation-silenced
 genes in human
 
esophageal cancer KYSE 510 cells. In this study, KYSE 510 cells treated with 5–50 µM of
 EGCG for 
12–144 h caused a concentration- and time-dependent
 reversal of hypermethylated p16
INK4a, retinoic 
acid receptor
 ß (RARß), MGMT, and human mutL homologue 1 (hMLH1) genes. 
It was also reported that in an epidemiological study conducted among 73 patients with gastric 
carcinoma, an increased
 intake of green tea was significantly associated
 with the Cdx2 methylation 
frequency (P = 0.02). The caudal-related homeobox transcription factor (Cdx2) is a tumor suppressor 
gene and frequently inactivated by methylation of its promoter in gastric carcinoma and colorectal 
cancer cells. Green tea could decrease the Cdx2 methylation frequency in a dose-dependent manner by 
60%, 61%, 75%, and 100% in patients who consumed three or less, four to six, seven to
 nine and ten 
cups or more a day, respectively [24]. 
2.1.3. Antioxidative Effect of Green Tea and (-)-EGCG and Cancer Prevention 
In the natural process of oxidation, human bodies produce free radicals. These molecules can cause 
damage to proteins, lipids and DNA, but are generally cleaned up by substances called antioxidants 
and systems of antioxidant enzymes before they can insult cells. Several human diseases have a strong 
association with the oxidative damage in tissues, such as cancer, heart disease, diabetes, Alzheimer's 
disease, and aging [25, 26]. The term antioxidant originally referred specifically to a chemical that Int. J. Mol. Sci. 2008, 9 
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prevented the consumption of molecular oxygen. Green tea is an important antioxidant in the diet. It 
has been shown that many of the antiproliferative effects of (-)-EGCG are attributable to its 
antioxidant properties [27]. Rah et al. [28] investigated the potential protective roles of green tea 
polyphenols (GTP) against the injurious effects of reactive oxygen species in human microvascular 
endothelial cells (HUMVECs). They found that the H2O2-induced alterations were completely 
prevented by pre-incubating the endothelial cells with 10 μg/ml GTP for 1 h. When the oxidative stress 
was induced by xanthine oxidase (XO), cell viability and morphology were also significantly 
maintained at the same GTP concentration. These results demonstrate that GTP can act as a biological 
antioxidant in a cell culture experimental model and prevent oxidative stress-induced cytotoxicity in 
the endothelial cells. 
Coimbra et al. [29] reported the effect of green tea in protecting the human body from oxidative 
stress diseases. In 34 human subjects, they evaluated the total antioxidant status (TAS), the two 
markers of lipid peroxidation products—malonyldialdehyde (MDA) and malonyldialdehyde+4-
hydroxy-2(E)-nonenal (MDA+4-HNE)—and the two markers of oxidative changes in erythrocyte 
membrane, called membrane bound haemoglobin (MBH) and band 3 (a transmembrane protein on 
erythrocyte) profile. After drinking green tea (1 liter of green tea daily for 4 weeks), they found a 
significant reduction in serum levels of MDA (by 30.37%) and MDA+4-HNE (by 39.10%) and in the 
oxidative stress within the erythrocyte, as measured by a significantly lower value of MBH (24.69%) 
and by changes in band 3 profile towards a normal mean profile [29]. In another in vivo study, the total 
antioxidant capacity of plasma in 10 healthy people was measured at baseline, 60 min and 120 min 
after ingestion of green tea. The results showed that the total antioxidant capacity of plasma increased 
by 1.1% at 60 min and 2.1% at 120 min over baseline value in subjects consuming 150 ml of green tea, 
which was statistically not significant. However, the total antioxidant capacity of plasma after 
consuming 300 ml of green tea showed a significant increase of 7.0% after 60 min, and 6.2% after 120 
min (P<0.0001). After consuming 450 ml of green tea, there was an increase to 12.0% after 60 min, 
and 12.7% after 120 min over baseline value (P<0.0001) [30]. 
2.2. Dietary Flavonoids 
Flavonoids belong to a subgroups of polyphenols and are widely distributed in the plant kingdom 
[31, 32]. Flavonoids constitute a large family of compounds including flavanols, flavones, flavonols, 
flavanones, anthocyanidins, proanthocyanidins and isoflavones [33]. The major sources of flavonoids 
are from dietary fruit and vegetables. It has been showed that flavonoids possess various biological 
functions including anti-inflammations, antioxidants and cancer prevention activities [2-5]. 
2.2.1. Genistein 
Genistein is an isoflavone compound and found in soy bean and related products such as Tofu, soy 
milk and soy sauce [34]. Genistein has been shown to inhibit tumor growth in mouse models of breast, 
prostate and skin cancers [35, 36]. It has been reported that genistein may protect against 
spontaneously developing prostate tumors in the transgenic adenocarcinoma of mouse prostate 
(TRAMP) model. TRAMP mice who were fed a 250 mg/kg diet of genistein significantly down-
regulated cell proliferation, EGFR, IGF-1R, ERK-1 and ERK-2 in prostates of TRAMP mice [37]. Int. J. Mol. Sci. 2008, 9 
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Treatment with genistein (20 μmol/L) inhibited cell proliferation in vitro by approximately 50% in 
estrogen-independent human breast cancer MDA-MB-231 cells. But in an in vivo study, genistein (750 
mg/kg AIN-93G diet), fed 3 d before the same cells were implanted into mice, did not significantly 
inhibit tumor formation or growth [38]. In another study of breast cancer mouse models, treatment of 
MCF-7 (estrogen-receptor positive) or MDA-MB-468 (estrogen-receptor negative) cell line with 
genistein before implantation into nude mice diminished tumorigenic potential of these cells [39].  
In a skin cancer mouse model study, topic application with genistein was shown to reduce tumor 
incidence and multiplicity in DMBA-initiated and TPA-promoted skin tumors on SENCAR mouse 
model by approximately 20 and 50%, respectively. The proposed mechanisms were probably through 
blockage of DNA adduct formation and inhibition of oxidative and inflammatory events in vivo [40]. 
Mice pretreated with genistein for 2 weeks by gavages had a decreased susceptibility toward DMBA-
mediated carcinogenesis on the skin and different organs, associated with increased activity of natural 
killer cells and increased cytotoxic T lymphocyte activity [41]. 
2.2.2. Apigenin, Luteolin, Quercetin and Kaempferol 
Apigenin and luteolin belong to flavones, and quercetin and kaempferol are flavonols compounds. 
All of them commonly found in a variety of vegetables: celery, broccoli, onions, peppers, and parsley 
[33, 42]. These dietary flavonoids have been shown to induce apoptotic cell death in human leukemia, 
Jurkat T cells, via inhibition of proteasome activity [43, 44]. It was found that the order of inhibitory 
potency against proteasome and potency of inducing apoptosis in Jurkat T cells was 
apigenin≥luteolin>quercetin>kaempferol. Through analysis of nucleophilic susceptibility in computer 
modeling, it was shown that a carbon at position 4 (C4) in C ring of flavonoids was an active atom with 
highest nucleophilic susceptibility to interact with target proteins [44]. By analysis of the structure-
activity relationship, we found that deletion of hydroxyl group at the C3 position would dramatically 
increase the potency of flavonoids to inhibit proteasome activity and induce apoptosis in malignant 
cells [44]. This finding will help researchers synthesize more potent compounds based on structure-
activity relationships of natural compounds. 
Apigenin was also shown to inhibit proteasome activity and induce apoptosis in human breast 
cancer MDA-MB-231 cells [45]. Treatment of nude mice bearing human breast cancer MDA-MB-231 
xenografts, with 25 or 50 mg/kg of apigenin for 29 days, showed 22% and 43% tumor growth 
inhibition, respectively, associated with inhibitory proteasome activity and induction of apoptosis [45]. 
Pretreatment with apigenin (20 and 50 μg/mouse/d) for 2 weeks followed by human prostate cancer 
22Rv1 cells implantation in nude mice, tumor volumes were reduced by 39% and 53%, respectively. 
In another PC-3 tumor model, treatment with apigenin resulted in 32% and 51% inhibition in tumor 
growth [46]. The proposed mechanism of anti-tumor activity by apigenin was upregulation of 
WAF1/p21, KIP1/p27, INK4a/p16, and down-modulation of the protein expression of cyclins D1, D2, 
E and cyclin-dependent kinases (cdk) [46]. 
2.3. Curcumin 
Curcumin (diferuloylmethane), a polyphenol compound found in both turmeric and curry powders, 
is known for its anticancer, antioxidant and anti-inflammatory activities [47-49]. Curcumin has been Int. J. Mol. Sci. 2008, 9 
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shown to inhibit the growth of transformed cells and to have a number of potential molecular targets. 
Curcumin has been shown to inhibit NF-κB and IκB-α kinase (IKK), leading to suppression of 
proliferation and apoptosis in cell lines of head and neck squamous cell carcinoma [50]. Curcumin has 
also been shown to suppress fibroblast growth
  factor-2 (FGF-2) induced angiogenesis through 
inhibition of expression of matrix metalloproteases (MMPs) in cultured corneal cells [51]. 
In animal model studies, treatment of hepatocellular carcinoma HepG2 cell-implanted nude mice 
with curcumin orally, inhibited tumor angiogenesis by measurement of tumor neocapillary density. 
Through analysis of related angiogenic biomarkers, it was found that expression of cycloxygenase 
(COX)-2 and serum level of vascular endothelial growth factor (VEGF) were significantly decreased 
in the curcumin-treated group [52]. In nude mice models, implanted with head and neck squamous cell 
carcinoma CAL 27 cells, treatment with curcumin inhibited tumor growth. The proposed mechanism 
was suppression of expression of NF-κB and cyclin D1 [53]. 
Curcumin appears to be stable at acidic pH, but unstable in neutral and basic pH [54, 55]. In 
contrast, tetrahydrocurcumin, one of curcumin’s major metabolites, is quite stable at neutral and basic 
pH  [56].  It was found that curcumin was more potent than  tetrahydrocurcumin to inhibit cell 
proliferation in cultured HepG2 cells. However, in HepG2 implanted nude mice, treatment with 
tetrahydrocurcumin resulted in more potent inhibition against angiogenesis than curcumin [57]. 
In a phase I clinical trial, curcumin was taken orally for 3 months for cancer patients. The serum 
concentration of curcumin peaked at 1 to 2 hours. The average peak serum concentrations after taking 
4, 6 and 8 g of curcumin, were 0.51, 0.63 and 1.77 μmol/L, respectively [58]. This study demonstrated 
that curcumin was not toxic to humans up to 8 g/day when taken orally for 3 months [58]. 
A phase II trial of curcumin in patients with advanced pancreatic cancer evaluated the toxicity and 
activity of curcumin. Patients were treated with 8 g of curcumin daily by mouth for two months. 
Eleven patients
 were evaluated for response, and 15 were evaluated for toxicity.
 The results suggest 
that curcumin is well tolerated and no toxicities
 have been observed. Four patients have stable disease 
for two to seven
 months, and one patient had a brief partial remission indicated by 73% reduction
 in 
tumor size, by Response Evaluation Criteria In Solid Tumors (RECIST) for one month [59]. More 
clinical trials are needed to evaluate its biologic activities and molecular targets in cancer patients. 
It should mention that in clinical trials of oral administration of curcumin
 to human cancer patients, 
the systemic availability and blood level of curcumin
  was found to be negligible, due
  to poor 
absorption of this compound [60, 61]. Therefore scientists have been developing higher bioavailability 
and more potent anticancer compounds through modifying and synthesizing
 analogues of curcumin.
 
Adams et al. reported that several synthesized curcumin analogs inhibited tumor cell growth with a 
higher potency than the commonly used chemotherapeutic drug, cisplatin, and one of the analogues 
was equal potent as the anti-angiogenic drug TNP-470 [62]. Another research group [63] synthesized 
more than 50 curcumin analogs through α, β-unsaturated ketone modification. Amount these analogs, 
three of them (named by authors as GO-Y016, GO-Y030 and GO-Y031) showed >30 times greater 
potency than natural curcumin for their cell growth-inhibitory activity in human colon cancer HCT116 
cells [63]. The possible mechanisms include decreased expression levels of oncoproteins,
 β-catenin, 
Ki-ras, cyclin D1, and ErbB-2, at concentrations
  much lower than those normally used for   
curcumin [63]. Int. J. Mol. Sci. 2008, 9 
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3. Conclusion 
Natural compounds have been extensively studied and have shown anti-carcinogenic activities by 
interfering with the initiation, development and progression of cancer through the modulation of 
various mechanisms including cellular proliferation, differentiation, apoptosis, angiogenesis, and 
metastasis. However, further investigations are needed, especially focusing on molecular targets, 
mechanism-based animal and clinical studies to fully realize their potential usages and biological 
activities. Additionally, biological activities of these natural compounds are generally not potent 
enough and higher concentrations would be required to achieve the expected biological effects. 
Furthermore there are bioavailability and stability issues associated with some natural compounds. 
Therefore, based on chemical structures of natural compounds to synthesize more analogical 
compounds with greater potency and more stable properties is another important topic for 
investigation. By comparison of the structure-activity relationship (SAR) between natural and synthetic 
compounds, scientists have developed a series of novel analog compounds with improved 
bioavailability and potency of antitumor activity, compared with the natural parent compounds. These 
synthetic compounds include a Pro-drug of EGCG synthesized in our laboratories [64] and curcumin 
analogs such as GO-Y016, GO-Y030 and GO-Y031 [63]. These successful examples will encourage 
researchers to synthesize, screen and discover more and better natural compound analogs that will 
eventually benefit cancer patients in the clinic. 
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